Drugs / FMT combined with chemotherapy plus immunotherapy
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07854977 Background | Nov 2026 → May 2029 expected | pancreatic ductal adenocarcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FMT combined with chemotherapy plus immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07854977 ↗ |
| Route | Intravenous | “5-FU 2400 mg/ m² day IV for every two weeks” NCT07854977 ↗ |